Back

Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation has no impact on recurrences, cardiovascular events and mortality - insights from the german ablation registry

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in arrhythmias and device therapy Catheter Ablation of Arrhythmias ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Ruben Schleberger

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

23 More presentations in this session

Presentation thumbnail
Left atrial dysfunction still exists in patients who obtain normal left atrial volume after successful ablation of atrial fibrillation.
Doctor H. Kawakami (Toon, JP)
Abstract Slides
Presentation thumbnail
Same day discharge after atrial fibrillation ablation is feasible and safe. Results of a prospective study in 1015 patients
Mr M. Viezelis (Odense, DK)
Abstract Slides
Presentation thumbnail
Benefits of early intervention with catheter ablation in patients with atrial fibrillation
Doctor S. Mohanty (Austin, US)
Abstract Slides
Presentation thumbnail
Cryoballoon ablation of atrial fibrillation in low and medium volume hospitals - experiences of the German REGIONAL registry
Doctor J. Michaelsen (Lingen, DE)
Abstract Slides
Presentation thumbnail
Accuracy comparison of the new and previous Kodex occlusion tool software versions to assess pulmonary vein occlusion in atrial fibrillation cryoablation
Doctor M. Polselli (Rome, IT)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in arrhythmias and device therapy

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET